[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.180.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1970

Live and Inactivated Adenovirus VaccinesClinical Evaluation of Efficacy in Prevention of Acute Respiratory Disease

Author Affiliations

Great Lakes, Ill

From the Epidemiology Division, US Naval Medical Research Unit No. 4, Great Lakes, Ill. Dr. Griffin is now with University of Tennessee College of Medicine, Memphis. Dr. Greenberg is now with Mayo Clinic and Research Foundation, Rochester, Minn.

Arch Intern Med. 1970;125(6):981-986. doi:10.1001/archinte.1970.00310060059005
Abstract

Clinical evaluation of a live orally administered adenovirus 4 vaccine was conducted at the Naval Training Center, Great Lakes, III. In a double-blind epidemiologic investigation the effectiveness of this newer vaccine was compared to that of two other inactivated adenovirus 4 vaccines and appropriate placebos in a population of 2,307 recruits. By detailed clinical examination of all participants requiring hospitalization (644 admissions), syndrome-specific incidences of acute undifferentiated respiratory disease (ARD) and of other respiratory syndromes were derived. Each of the adenovirus vaccines effected a similar 50% to 60% relative reduction of ARD, as well as symptomspecific decreases in the incidence of clinical manifestations of ARD. No evidence of a clinical toxic effect of the live adenovirus vaccine administered orally was detected.

×